Component

Urinary N1-methylnicotinamide excretion

Urinary N1-methylnicotinamide excretion. The model and exposure of each linked claim define its scope.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In the selected NET cohort, mean plasma tryptophan was 31.8 micromol/L and 45% had urinary N1-methylnicotinamide below the study reference range.

    Serotonin-producing neuroendocrine tumor state → Urinary N1-methylnicotinamide excretion source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    cross_nutrient
    L-Tryptophan (measured_precursor); N1-methylnicotinamide (measured_metabolite)
    evidence_span
    {"source_cache": "artifacts/niacin-clinical-sources/bouma2016.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497", "start_char": 0, "end_char": 1869, "text_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497"}
    experimental_model
    Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references
    exposure
    Patients selected for low tryptophan and/or pellagra-associated symptoms; prescribed oral niacin mean 144 mg/day
    limitations
    No randomized comparator or direct tracer measurement of tryptophan diversion. Biomarker normalization does not establish symptom cure. Indexed abstract does not unambiguously specify the administered chemical form; retain niacin rather than guessing nicotinamide.
    nutrient_topic
    Niacin research collection; topical membership is not evidence of a direct dietary effect. · Niacin (vitamin B3)
    organism
    Homo sapiens
    plain_language
    In some serotonin-producing tumor patients, low tryptophan was accompanied by a low niacin marker.
    primary_references
    [nia-clin-bouma2016] Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. (2016). https://pubmed.ncbi.nlm.nih.gov/26335390/ DOI: 10.1159/000440621
    tissue_or_cell_type
    Plasma and urine
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17) · lines 1263–1275

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references · source_derived_draft · unverified_draft

    ### nia-clin-net-low-marker In the selected NET cohort, mean plasma tryptophan was 31.8 micromol/L and 45% had urinary N1-methylnicotinamide below the study reference range. Condition category: biomarker_context nutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect. plain_language: In some serotonin-producing tumor patients, low tryptophan was accompanied by a low niacin marker. organism: Homo sapiens tissue_or_cell_type: Plasma and urine experimental_model: Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references limitations: No randomized comparator or direct tracer measurement of tryptophan diversion. Biomarker normalization does not establish symptom cure. Indexed abstract does not unambiguously specify the administered chemical form; retain niacin rather than guessing nicotinamide. exposure: Patients selected for low tryptophan and/or pellagra-associated symptoms; prescribed oral niacin mean 144 mg/day cross_nutrient: L-Tryptophan (measured_precursor); N1-methylnicotinamide (measured_metabolite) evidence_span: {"source_cache": "artifacts/niacin-clinical-sources/bouma2016.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497", "start_char": 0, "end_char": 1869, "text_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497"} [nia-clin-bouma2016] Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. (2016). https://pubmed.ncbi.nlm.nih.gov/26335390/ DOI: 10.1159/000440621
    Complete structured claim and evidence

  2. Urinary N1-methylnicotinamide rose into the high-normal range in 86% of initially niacin-deficient patients after supplementation in this retrospective series.

    Niacin (vitamin B3) → Urinary N1-methylnicotinamide excretion source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    cross_nutrient
    N1-methylnicotinamide (measured_metabolite)
    evidence_span
    {"source_cache": "artifacts/niacin-clinical-sources/bouma2016.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497", "start_char": 0, "end_char": 1869, "text_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497"}
    experimental_model
    Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references
    exposure
    Patients selected for low tryptophan and/or pellagra-associated symptoms; prescribed oral niacin mean 144 mg/day
    limitations
    No randomized comparator or direct tracer measurement of tryptophan diversion. Biomarker normalization does not establish symptom cure. Indexed abstract does not unambiguously specify the administered chemical form; retain niacin rather than guessing nicotinamide.
    nutrient_topic
    Niacin research collection; topical membership is not evidence of a direct dietary effect. · Niacin (vitamin B3)
    organism
    Homo sapiens
    plain_language
    Supplementation improved the measured niacin-status marker for most deficient patients in this series.
    primary_references
    [nia-clin-bouma2016] Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. (2016). https://pubmed.ncbi.nlm.nih.gov/26335390/ DOI: 10.1159/000440621
    tissue_or_cell_type
    Plasma and urine
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17) · lines 1277–1289

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references · source_derived_draft · unverified_draft

    ### nia-clin-net-supplement-marker Urinary N1-methylnicotinamide rose into the high-normal range in 86% of initially niacin-deficient patients after supplementation in this retrospective series. Condition category: biomarker_context nutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Supplementation improved the measured niacin-status marker for most deficient patients in this series. organism: Homo sapiens tissue_or_cell_type: Plasma and urine experimental_model: Retrospective serotonin-producing NET cohort; 42 baseline and 34 paired samples; 133 healthy urine references limitations: No randomized comparator or direct tracer measurement of tryptophan diversion. Biomarker normalization does not establish symptom cure. Indexed abstract does not unambiguously specify the administered chemical form; retain niacin rather than guessing nicotinamide. exposure: Patients selected for low tryptophan and/or pellagra-associated symptoms; prescribed oral niacin mean 144 mg/day cross_nutrient: N1-methylnicotinamide (measured_metabolite) evidence_span: {"source_cache": "artifacts/niacin-clinical-sources/bouma2016.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497", "start_char": 0, "end_char": 1869, "text_sha256": "1c1db5a8c0880ceda2066e1fcf23020ab293689782b99402d9913ff326917497"} [nia-clin-bouma2016] Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. (2016). https://pubmed.ncbi.nlm.nih.gov/26335390/ DOI: 10.1159/000440621
    Complete structured claim and evidence

  3. Urinary N1-methylnicotinamide below 1.2 mg/day identified the lowest 6.1-NE/day intake in this experiment and was more responsive than 2PY to the 10.1-NE/day diet.

    Niacin (vitamin B3) → Urinary N1-methylnicotinamide excretion source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    nutrient_deficiency Imported condition classification; unverified.
    cross_nutrient
    N1-methylnicotinamide (measured_metabolite)
    evidence_span
    {"source_cache": "artifacts/niacin-clinical-sources/jacob1989.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "749fc69d8d6cb1ba79a0b17e38e9300611713e3939224ba9ac809cef91c7a64c", "start_char": 0, "end_char": 1463, "text_sha256": "749fc69d8d6cb1ba79a0b17e38e9300611713e3939224ba9ac809cef91c7a64c"}
    experimental_model
    Controlled metabolic-unit feeding of young men for 11 weeks
    exposure
    6.1–32 NE/day; oral nicotinamide test doses
    limitations
    Small controlled male metabolic-unit study. Erythrocytes are not every tissue; historical adequate intake is not a current recommendation. Jacob and Fu reports may describe related participants and are not counted as independent trials. Historical NMN abbreviation means N1-methylnicotinamide, not nicotinamide mononucleotide. Urinary output is not a universal diagnostic cutoff.
    nutrient_topic
    Niacin research collection; topical membership is not evidence of a direct dietary effect. · Niacin (vitamin B3)
    organism
    Homo sapiens
    plain_language
    Less niacin intake left less methylated niacin waste in urine; the study threshold belongs to this particular experiment.
    primary_references
    [nia-clin-jacob1989] Biochemical markers for assessment of niacin status in young men: urinary and blood levels of niacin metabolites. (1989). https://pubmed.ncbi.nlm.nih.gov/2522982/ DOI: 10.1093/jn/119.4.591
    tissue_or_cell_type
    Urine and plasma
    trigger_kind
    nutrient_deficiency Imported condition classification; unverified.

    Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17) · lines 1149–1161

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Controlled metabolic-unit feeding of young men for 11 weeks · source_derived_draft · unverified_draft

    ### nia-clin-urine-mna-restriction Urinary N1-methylnicotinamide below 1.2 mg/day identified the lowest 6.1-NE/day intake in this experiment and was more responsive than 2PY to the 10.1-NE/day diet. Condition category: nutrient_deficiency nutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Less niacin intake left less methylated niacin waste in urine; the study threshold belongs to this particular experiment. organism: Homo sapiens tissue_or_cell_type: Urine and plasma experimental_model: Controlled metabolic-unit feeding of young men for 11 weeks limitations: Small controlled male metabolic-unit study. Erythrocytes are not every tissue; historical adequate intake is not a current recommendation. Jacob and Fu reports may describe related participants and are not counted as independent trials. Historical NMN abbreviation means N1-methylnicotinamide, not nicotinamide mononucleotide. Urinary output is not a universal diagnostic cutoff. exposure: 6.1–32 NE/day; oral nicotinamide test doses cross_nutrient: N1-methylnicotinamide (measured_metabolite) evidence_span: {"source_cache": "artifacts/niacin-clinical-sources/jacob1989.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "749fc69d8d6cb1ba79a0b17e38e9300611713e3939224ba9ac809cef91c7a64c", "start_char": 0, "end_char": 1463, "text_sha256": "749fc69d8d6cb1ba79a0b17e38e9300611713e3939224ba9ac809cef91c7a64c"} [nia-clin-jacob1989] Biochemical markers for assessment of niacin status in young men: urinary and blood levels of niacin metabolites. (1989). https://pubmed.ncbi.nlm.nih.gov/2522982/ DOI: 10.1093/jn/119.4.591
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards